ORIGINAL ARTICLE
Year : 2012  |  Volume : 4  |  Issue : 1  |  Page : 43-50

Topical application of green tea polyphenol (−) epigallocatechin-3-gallate for prevention of recurrent oral neoplastic lesions


1 Division of Oral and Maxillofacial Pathology, Columbia University Medical Center, New York, USA
2 Department of Environmental Health Sciences, Columbia University Medical Center, New York, USA
3 Division of Oral and Maxillofacial Surgery, Columbia University Medical Center, New York, USA
4 Department of Head and Neck Surgery, Columbia University Medical Center, New York, USA

Correspondence Address:
Angela J Yoon
630 West 168th Street, PH15W-1562, New York, NY 10032
USA
Login to access the Email id

Source of Support: This work was supported by a K12 Career Development Award (A. Yoon) provided through the Clinical and Translational Science Award KL2 RRO24157 (H. Ginsberg) from the NCRR/NIH, UL1 RR024156 from NCRR/NIH (H. Ginsberg) and NIEHS/NIH grant P30 ES009089 (R. Santella), Conflict of Interest: None


DOI: 10.4103/0975-8844.99891

Rights and Permissions

Objective: A preliminary study was conducted to investigate the feasibility of using an oral cancer chemopreventive agent (−)-epigallocatechin-3-gallate (EGCG), the most biologically active component in the green tea extract, in a form of "swish-and-spit" mouthwash. Such application of EGCG is beneficial as it maximizes exposure of the oral mucosa to the agent but minimizes systemic side effect. Materials and Methods: The study was conducted on individuals suspected to have oral field cancerization who are at a high risk for developing recurrent oral precancerous and carcinomatous lesions. EGCG was used as a daily mouthwash for 7 days. EGCG's ability to modulate target molecules implicated in oral carcinogenesis was assessed by measuring the change in the expression levels of biomarkers. Results: Immunohistochemical expressions of phosphoactivated epidermal growth factor receptor (pEGFR), cyclooxygenase-2 (cox-2), and ki-67 were evaluated at baseline and at the endpoint (day 8). Although not statistically significant, overall decrease in expression levels of pEGFR (27.5%), cox-2 (15.9%), and ki-67 positive cells (51.8%) was observed following EGCG treatment. Moreover, a detectable level of EGCG was found in saliva but not in plasma after the 1-week treatment regime, demonstrating local availability of EGCG in oral mucosa without significant systemic absorption. Conclusion: To the best of our knowledge, this is the first study to explore use of oral cancer chemopreventive agent in the form of mouthwash in patients with oral field cancerization. Although a definitive conclusion was not reached due to limited sample size, if proven effective, EGCG therapy may offer a non-invasive preventive modality for oral field cancerization.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed2886    
    Printed114    
    Emailed0    
    PDF Downloaded330    
    Comments [Add]    
    Cited by others 7    

Recommend this journal